Journals / Çocuk Enfeksiyon Dergisi / 2011 / Cilt: 5 - Sayı: 4

Complication of BCG Vaccination: BCG-itis

Aşı Komplikasyonu: BCG-itis

Pages
148–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We report a patient who presented with a specific complication which is an erythematous nodule after BCG vaccination, and diagnosed as BCG-itis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bacilli Calmette-Guérin (BCG) is a type of Mycobacterium bovis species bearing all the structural features of M. tuberculosis but no disease has been described due to M. bovis.
📊
Key Findings & Data:BCG vaccine is indicated for prevention of this disease via stimulation of the development of active immunity against tuberculosis.
💡
Conclusion & Impact:We report a patient who presented with a specific complication which is an erythematous nodule after BCG vaccination, and diagnosed as BCG-itis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Bacilli Calmette-Guérin (BCG) is a type of Mycobacterium bovis species bearing all the structural features of M. tuberculosis but no disease has been described due to M. bovis. BCG vaccine is indicated for prevention of this disease via stimulation of the development of active immunity against tuberculosis. Vaccination, especially during the first decade of life in children, protects against the risk of tuberculosis and tuberculosis meningitis. The BCG vaccine has a high reliability. Various skin lesions after vaccination are rare complications. We report a patient who presented with a specific complication which is an erythematous nodule after BCG vaccination, and diagnosed as BCG-itis.

Özet

Bacille Calmette-Guérin (BCG), tüberküloz basilinin bütün yapısal özelliklerini taşıyan, ancak hastalık oluşturma yeteneği yok edilmiş bir Mycobacterium bovis suşudur. BCG aşısı, tüberküloza karşı aktif bağışıklık gelişmesini stimule etmek suretiyle bu hastalığın önlenmesinde endikedir. Aşının hayatın ilk dönemlerinde yapılması, özellikle çocukluk çağı tüberkülozu ve tüberküloz menenjit riskine karşı koruma sağlar. BCG aşısının güvenilirliği yüksektir. Aşıdan sonra nadir görülen komplikasyonlar arasında çeşitli cilt lezyonları da yer almaktadır. Biz bu olgu sunumuyla, BCG aşısı sonrası eritematöz bir nodülle başvuran ve BCG aşısının çok özel bir cilt komplikasyonu olan BCG-itis tanılı bir hastayı sunduk.

🔖

Cite This Article

KILIÇ, B., DALGIÇ, N., BAYRAKTAR, B., GENCER, H. (2011). Complication of BCG Vaccination: BCG-itis. Çocuk Enfeksiyon Dergisi, Cilt: 5 - Sayı: 4, 148–152. https://ajindex.com/articles/214725

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Global tuberculosis control: WHO report 2010. Genova, Switzerland: 2010
  2. Fine PEM. Bacille Calmette-Guerin vaccines: A rough guide. Clin Infect Dis1995; 20: 11-4. [CrossRef] 3. Toida I, Nakata S. Severe adverse reactions after vaccination with Japanese BCG vaccine: a review. Kekkaku 2007; 82: 809-24
  3. Smith KC, Starke JR. Bacille-Calmette-Guerin Vaccine. In: Plotkin SA, Orenstein WA (eds). Vaccines. 3rd edition. Philadelphia: WB Saunders Company, USA; 1999. p. 111-95
  4. Shoenfeld Y, Aron Maor A. Vaccination an autoimmunity- vaccinosis: a dangerous liaison? J Autoimmun 2000; 14: 1-10. [CrossRef] 6. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated Bacille Calmette Guerin disease after vaccination: Case report and review. Clin Infect Dis 1997; 98: 774-8
  5. Bellet JS, Prose NS. Skin complications of Bacillus Calmette Guerin immunization Curr Opin Infect Dis 2005; 18: 97-100. [CrossRef] 8. Keijsers RR, Bovenschen HJ, Seyger MM. Cutaneous complication after BCG vaccination: Case report and review. J Dermatolog Treat 2010; 1-4
  6. Nazir Z, Qazi S. Bacille calmette-guerin (BCG) lymohadenitischanging trends and management. J Ayub Med Coll Abbottabad 2005; 17: 16-8
  7. Hanley SP, Gumb J, MacFarlane JT. Comparison of erythromycin and isoniazid in treatment of adverse reactions to BCG vaccination. Br Med J (Clin Res Ed) 1985; 290: 970. [CrossRef] 11. Ali S, Almoudaris M. BCG lympadenitis. Arch Dis Child 2004; 89: 812. [CrossRef] 12. Hlavsa MC, Moonan PK, Cowan LS, et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis 2008; 47: 168-75. [CrossRef] 13. Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA. Tuberculosis from Mycobacterium bovis in binational communities, United States. Emerg Infect Dis 2008; 14: 909-16. [CrossRef] 14. Centers for Disease Control AND Prevention (CDC). Human tuberculosis caused by Mycobacterium bovis-New York City, 2001-2004. MMWR Morb Mortal Wkly Rep 2005; 54: 605-8
  8. Özkınay F, Özkınay C. BCG, Yeni TB Aşıları ve PPD. J Pediatr Inf 2008; 2: 1-6.